NeuroMetrix (NURO) investor relations material

Executive summary

• Q3 2024 revenue declined 51% year-over-year to $0.6M, mainly due to lower DPNCheck sales from adverse Medicare Advantage reimbursement changes and international distributor inventory issues, with Quell sales providing a minor offset.

• Net loss for Q3 2024 was $1.5M ($0.75/share), improved from $1.8M ($1.66/share) in Q3 2023, as operating expenses fell 25% year-over-year due to headcount reduction and cost-cutting measures.

• Gross profit dropped 60% year-over-year, with gross margin contracting to 53.1% from 65.0%, reflecting lower DPNCheck sales and product mix.

• The company is conducting a strategic review, including potential asset sales, mergers, or changes in marketing, with no set timetable for completion.

• Company is actively reviewing strategic alternatives to enhance shareholder value.

Financial highlights

• Q3 2024 revenue: $0.6M (down 51% year-over-year); nine months ended September 30, 2024: $2.5M (down 47%).

• Q3 2024 gross profit: $0.3M (down 60% year-over-year); gross margin 53.1% vs. 65.0% prior year.

• Q3 2024 operating expenses: $2.1M (down 25% year-over-year); nine months: $8.1M (down 3%).

• Q3 2024 net loss: $1.5M; nine months: $6.0M (vs. $4.9M prior year).

• Cash, cash equivalents, and marketable securities at September 30, 2024: $14.8M; working capital: $15.6M; no debt.

Outlook and guidance

• Management expects current cash and securities to fund operations for at least the next twelve months.

• DPNCheck Medicare Advantage sales are unlikely to recover near-term due to ongoing CMS reimbursement changes; international DPNCheck sales expected to resume in early 2025 as distributor inventory normalizes.

• Quell Rx for fibromyalgia is in controlled launch; De Novo application for Quell-CIPN planned for late 2024 or early 2025.

• Company continues to pursue opportunities in alternative markets for DPNCheck.